The DCUN1D1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B-lymphocyte cell line. This product features targeted disruption of the DCUN1D1 gene, which encodes a scaffold protein essential for cullin neddylation. The polyclonal format provides a bulk mixture of knockout cells generated by CRISPR/Cas9-mediated gene disruption, suitable for studying neddylation dynamics in a lymphoma context.
Raji cells are Epstein-Barr virus-positive B lymphocytes from a Burkitt lymphoma patient, widely used in immunology and cancer research. This cell line exhibits constitutive NF-??B activity and defective apoptosis, making it a relevant model for B-cell malignancies and investigations into protein homeostasis, stress signaling, and therapeutic vulnerabilities.
DCUN1D1 facilitates cullin neddylation by binding both UBE2M~NEDD8 and cullin-RBX1 complexes, promoting NEDD8 transfer and activating cullin-RING E3 ligases (CRLs). CRLs ubiquitinate substrates including p27, p21, I??B??, and HIF-1??, regulating cell cycle, NF-??B signaling, and hypoxia response. DCUN1D1 expression is controlled by the E2F1 transcription factor and ATM/ATR-dependent DNA damage pathways. Knockout of DCUN1D1 impairs neddylation, inactivates CRLs, and stabilizes substrate proteins.
In Raji lymphoma cells, loss of DCUN1D1 disrupts cullin neddylation and CRL activity, leading to altered turnover of key regulators. This perturbation may impact cell cycle progression, DNA damage responses, and NF-??B-mediated transcription. The knockout model thus serves as a relevant tool for dissecting neddylation-dependent mechanisms in B-cell malignancy and for evaluating inhibitors like MLN4924 in a lymphoma setting.
These polyclonal knockout cells support a variety of applications: Western blotting for cullin neddylation status, RT-qPCR for DCUN1D1 expression, co-immunoprecipitation to probe interactions with UBE2M or CUL1, and ubiquitination assays to track substrate dynamics. Flow cytometry enables cell cycle analysis, while apoptosis assays assess stress responses. Drug sensitivity studies with MLN4924 can link neddylation to compound efficacy. These tools facilitate cancer biology, ubiquitin-proteasome, and lymphoma research. For additional information, please contact Ascent Research.
